BeOne Medicines (49BA) AI Stock Analysis

4 Followers

BeOne Medicines

(Frankfurt:49BA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Profitable growth and cash generationThe company has converted rapid revenue growth into meaningful profitability and cash generation, with high gross margins and strong free-cash-flow conversion. This improves self-funding capacity for commercialization and pipeline investment while strengthening financial resilience over the next several quarters.

Negative Factors

Historical earnings volatilityThe recent profitability inflection remains exposed to execution risk because the company previously generated sizable losses while expanding. If spending rises faster than product growth or launches underperform, earnings and equity could again face pressure, reducing the durability of the turnaround.

BeOne Medicines (49BA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 44.88B
Dividend Yield: ―
Average Volume (3M): 15
Price to Earnings (P/E): 68.5
Beta (1Y): 0.80
Revenue Growth: 26.78%
EPS Growth: 1621.41%
Country: Germany
Employees: 12,000
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

BeOne Medicines Business Overview & Revenue Model

Company Description

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule...

BeOne Medicines Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:10.18%|Next Earnings Date:Mar 31, 2027

Earnings Call SentimentPositive

The call was strongly positive, characterized by 33% product revenue growth, substantially higher operating income and free cash flow, raised 2026 guidance, sustained BRUKINSA momentum, and broad progress across hematology and solid tumor programs. The main challenges were the approximately $50 million order-timing benefit, future revenue pressure from biosimilars and potential VBP inclusion, a statutory Medicare Part D headwind, a PHESGO impairment charge, a more modest pace of future margin expansion, and the delayed tacabrutideg filing. Highlights significantly outweighed lowlights.

Positive Updates

Strong Q3 Revenue Growth and Profitability

Product revenue grew 33% year-over-year to approximately $1.9 billion, while total revenue increased to $1.9 billion from $1.4 billion in the prior year. Income from operations grew 157% to $419 million, net income was $385 million, and GAAP diluted earnings per ADS rose to $3.28 from $1.09.

Negative Updates

BRUKINSA Revenue Benefited from Order Timing

U.S. BRUKINSA sales included an approximately $50 million tailwind from order timing, including an extra shipping day in the quarter.

Company Guidance

For 2026, BeOne Medicines raised and narrowed guidance to total revenue of $6.9 billion-$7 billion, gross margin in the high 80% range, operating expenses of $4.9 billion-$5 billion, GAAP operating income of $1.2 billion-$1.3 billion, and non-GAAP operating income of $1.9 billion-$2 billion; it expects a modest net pricing benefit in the U.S. for BRUKINSA for the balance of the year, while looking ahead to 2027, it expects relatively stable net pricing and a flat to modest headwind from the increase in Medicare Part D manufacturer liability, operating expenses growth to be at least consistent with where we have been over the past several years, operating income to continue to grow meaningfully, and the pace of margin expansion to be modest as compared to 2025 and 2026; the current expectation is that the income tax valuation allowance reversal will occur in the fourth quarter and result in a material tax benefit.

BeOne Medicines Risk Analysis

BeOne Medicines disclosed 93 risk factors in its most recent earnings report. BeOne Medicines reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Below is a summary of the material factors that make an investment in our ADSs listed on Nasdaq, our ordinary shares listed on the Stock Exchange of Hong Kong Limited, and our ordinary shares issued to permitted investors in China and listed and traded on the Science and Technology Innovation Board of the Shanghai Stock Exchange in Renminbi ("RMB Shares") speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, are set forth herein and should be carefully considered, together with other information in this Quarterly Report and our other filings with the U.S. Securities and Exchange Commission ("SEC"), before making an investment decision regarding our ADSs, ordinary shares or RMB Shares.Q1, 2026

2.The risk factors denoted with a "*", if any, are newly added or have been materially updated from our Annual Report on Form 10-K for the year ended December 31, 2025 (the "Annual Report").Q1, 2026

BeOne Medicines Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:49BA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	81Outperform	$17.22B	20.49	45.54%	―	9.12%	40.53%
INCY	68Neutral	$24.52B	58.22	7.11%	―	24.88%	-65.67%
GMAB	63Neutral	$31.77B	44.48	12.26%	―	19.61%	-50.40%
SMMT	56Neutral	$14.26B	-15.55	-138.81%	―	―	13.96%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZLAB	51Neutral	$3.42B	-14.28	-31.11%	―	0.25%	8.33%

* Healthcare Sector Average

Performance Comparison

DE:49BA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:49BA	BeOne Medicines	368.00	46.00	14.29%
EXEL	Exelixis	70.70	28.35	66.94%
INCY	Incyte	122.27	16.86	15.99%
SMMT	Summit Therapeutics PLC	16.64	-1.62	-8.87%
ZLAB	Zai Lab Ltd	26.42	4.69	21.58%
GMAB	Genmab (Otc)	53.87	23.63	78.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BeOne Medicines AI Stock Analysis